Urotronic
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Urotronic sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Urotronic: 8 sponsored US clinical trials, 4 recruiting.
Urotronic sponsors 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Benign Prostatic Hyperplasia, with 3 trials.
Upper-quartile sponsor footprint
Urotronic sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
EvaluatioN of Optilume Drug-Coated Balloon for the Endoscopic Treatment of UREteric Strictures
NCT07020520
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
NCT06560476
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
NCT06312722
Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters
NCT05383274
Optilume™ BPH Catheter System in Men With Symptomatic BPH
NCT04131907
ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
NCT03499964
Re-establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
NCT03270384
ROBUST I Pilot Study, Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
NCT03014726
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Urotronic pipeline
4 recruiting of 8 indexed (50% open); 2 completed (25%).
Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).
Top condition: Benign Prostatic Hyperplasia (3 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Urotronic: open-pipeline peers nationwide
Peers matched on 8 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Urotronic sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
Related
What to do with this Urotronic page
8 registered trials is a research-attention snapshot, not an endorsement of Urotronic or any single study.
- 4 of Urotronic's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Benign Prostatic Hyperplasia is the condition Urotronic studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Benign Prostatic Hyperplasia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Urotronic pipeline card: 8 registered trials from official public datasets.Report a data error.